Clinical trials: Stage III Esophageal Squamous Cell Carcinoma
Squamous Cell Esophageal Carcinoma, Esophageal Cancer
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
The primary objective is to compare PD-1 inhibitor combined with preoperative chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery, in terms of the overall survival time (OS) in patients…
- Conditions
- Squamous Cell Esophageal Carcinoma, Esophageal Cancer, Oesophageal Cancer
- Trial name
- NCT05357846
- Testing
- Sintilimab, Preoperative radiotherapy, Paclitaxel
- Where
- China
- Volunteers
- 422 people
- Sponsor
- Sun Yat-sen University
Stage III Esophageal Squamous Cell Carcinoma, Stage II Esophageal Squamous Cell Carcinoma
Different Cycles of Cisplatin-5-fluorouracil for the Chemoradiotherapy of Esophageal Squamous Cancer
A two-arm Phase III trial was started in Oct. 2014. Definitive chemoradiotherapy with cisplatin plus 5-fluorouracil is the standard in Western countries in esophagus cancer.
- Trial name
- PFCRTESC (NCT02607540)
- Testing
- 2 cycles cisplatin-5-fluorouracil, 4 cycles cisplatin-5-fluorouracil, Radiotherapy
- Where
- China
- Volunteers
- 210 people
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
Esophageal Squamous Cell Carcinoma
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
The purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo in participants with unresectable esophageal squamous cell carcinoma (or those who are unable or unwilling to…
- Trial name
- SKYSCRAPER-07 (NCT04543617)
- Testing
- Tiragolumab, Atezolizumab
- Where
- 166 sites in United States, Argentina and 26 more
- Volunteers
- 760 people
- Sponsor
- Hoffmann-La Roche
Esophageal Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced or Metastatic Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002984
- Testing
- cisplatin, fluorouracil, paclitaxel
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Esophageal Carcinoma, Radiotherapy
TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC
The goal of this clinical trial is to learn if immunotherapy in combination with tumor draining lymph nodes-sparing radiotherapy (TDLN-sparing RT) and chemotherapy works to treat locally advanced esophageal squamous cell cancer…
- Conditions
- Esophageal Carcinoma, Radiotherapy, Immunotherapy
- Trial name
- NCT06676449
- Testing
- Immunotherapy, chemotherapy: Paclitaxel/Cisplatin or other guideline recommended regimens, TDLN-sparing RT
- Where
- China
- Volunteers
- 432 people
- Sponsor
- Fudan University
Esophageal Cancer
Surgery With or Without Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003118
- Testing
- cisplatin, fluorouracil, surgical procedure
- Where
- 38 sites in United States
- Volunteers
- 56 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Esophageal Squamous Cell Carcinoma Abdominal Stage 0
PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC
This trial is a prospective, multicenter, randomized controlled trial. The sample size was 380. Patients with advanced or metastatic esophageal squamous cell carcinoma will be randomized to receive PD1 antibody combined with…
- Trial name
- Escape (NCT05737563)
- Testing
- PD-1 Inhibitors, Irinotecan, Capecitabine tablets
- Where
- China
- Volunteers
- 380 people
- Sponsor
- Sun Yat-sen University
Esophageal Squamous Cell Carcinoma
Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma
The purpose of this study is to determined the best definitive radiotherapy dosage for patients with locally advanced esophageal squamous cell carcinoma.
- Trial name
- NCT03790553
- Testing
- Radiotherapy
- Where
- 3 sites in China
- Volunteers
- 646 people
- Sponsor
- Fudan University
Esophageal Cancer
Cetuximab, Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00445861
- Testing
- cetuximab + docetaxel + cisplatin, Treatment level 1, Treatment level 2
- Where
- 2 sites in Switzerland
- Volunteers
- 27 people
- Sponsor
- Swiss Cancer Institute
Stage I Adenoid Cystic Carcinoma of the Oral Cavity, Stage I Mucoepidermoid Carcinoma of the Oral Cavity
Esophagoscopy in Evaluating Treatment in Patients With Stage I-IV Head and Neck Cancer Who Are Undergoing Radiation Therapy and/or Chemotherapy
Brief Summary: RATIONALE: Comparing results of diagnostic procedures, such as esophagoscopy, done before and after radiation therapy and/or chemotherapy may help doctors predict a patient's response to treatment and help plan the…
- Conditions
- Stage I Adenoid Cystic Carcinoma of the Oral Cavity, Stage I Mucoepidermoid Carcinoma of the Oral Cavity, Stage I Squamous Cell Carcinoma of the Hypopharynx, Stage I Squamous Cell Carcinoma of the Larynx
- Trial name
- NCT01164566
- Testing
- endoscopic procedure, questionnaire administration
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Wake Forest University Health Sciences
Esophageal Squamous Cell Carcinoma (ESCC)
PD-1 Inhibitors Combined With Local Therapy at Different Timings in Oligometastatic ESCC
Although immunotherapy combined with chemotherapy has become the first-line standard regimen for advanced esophageal squamous cell carcinoma (ESCC) and improved clinical outcomes in advanced patients, the prognosis of patients…
- Trial name
- ESO-shanghai31 (NCT07697859)
- Testing
- Two arms adopt local intervention administered at distinct timings.
- Where
- China
- Volunteers
- 354 people
- Sponsor
- Fudan University
Esophageal Squamous Cell Carcinoma
A Randomized Controlled Trial Evaluating of Prophylactic Irradiation in CRT for cT1bN0M0 ESCC
This study is conducted to investigate whether modified chemoradiotherapy with elective nodal irradiation reduces the locoregional recurrence that cannot be completely resected by salvage endoscopic resection and preserve…
- Trial name
- ARMADILLO (NCT04328948)
- Testing
- Chemoradiotherapy
- Where
- Japan
- Volunteers
- 280 people
- Sponsor
- National Cancer Center, Japan
Esophageal Cancer
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00030862
- Testing
- cisplatin, irinotecan hydrochloride
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Esophageal Squamous Cell Carcinoma
A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy
This is a large clinical study carried out at multiple hospitals. Participants will be randomly assigned to one of two groups: one group will receive a new medicine called YL201, and the other group will receive standard…
- Trial name
- NCT07487896
- Testing
- YL201, Paclitaxel, Docetaxel
- Where
- 81 sites in China
- Volunteers
- 440 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Prosthesis Survival
A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma
Esophageal cancer is the sixth leading cause of cancer death in worldwide. Over the past 2 decades, well-designed clinical trials have documented the clinical benefits of combination of chemotherapy and radiation for localized…
- Trial name
- NCT02409186
- Testing
- Nimotuzumab, radiotherapy, chemoradiotherapy Paclitaxel
- Where
- 14 sites in China
- Volunteers
- 200 people
- Sponsor
- Shandong Cancer Hospital and Institute
Esophageal Squamous Cell Carcinoma
Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma
Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma
- Trial name
- NCT02677597
- Testing
- Cisplatin Combined With S-1, Cisplatin Combined With Paclitaxel
- Where
- China
- Volunteers
- 268 people
- Sponsor
- Fudan University
Esophageal Cancer
Surgery With or Without Chemotherapy in Treating Patients With Stage II or Stage III Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not known whether chemotherapy before surgery is more effective than surgery alone in treating cancer…
- Trial name
- NCT00002897
- Testing
- cisplatin, fluorouracil, conventional surgery
- Where
- Italy
- Volunteers
- 240 people
- Sponsor
- European Institute of Oncology
Esophageal Cancer
Oxaliplatin and Fluorouracil Plus Radiation Therapy in Treating Patients With Primary Esophageal or Stomach Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004257
- Testing
- fluorouracil, oxaliplatin, conventional surgery
- Where
- United States
- Sponsor
- Albany Medical College
Esophageal Neoplasm
Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma
The effect of neo-adjuvant chemotherapy on survival of patients with thoracic esophageal squamous cell carcinomas remains the most controversial part of neo-adjuvant therapy for esophageal carcinomas.
- Trial name
- NCT02395705
- Testing
- cisplatin and paclitaxel
- Where
- 9 sites in China
- Volunteers
- 528 people
- Sponsor
- Henan Cancer Hospital
Esophageal Cancer
Celecoxib, Paclitaxel, and Carboplatin in Treating Patients With Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00066716
- Testing
- carboplatin, celecoxib, paclitaxel
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Weill Medical College of Cornell University